Cingulate (CING) vs NeOnc Technologies (NTHI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cingulate (CING) has outperformed NeOnc Technologies (NTHI) over the past year, gaining 15.9% versus a loss of 79.1%. NeOnc Technologies is the larger company by market cap ($72.9 million vs $71.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CING | NTHI |
|---|---|---|
| Share price | $4.88 | $2.53 |
| Market cap | $70.96M | $72.88M |
| 1-day change | +0.21% | -6.64% |
| YTD return | +12.44% | -69.41% |
| 1-year return | +15.91% | -79.07% |
| EPS (TTM) | $-3.51 | $-2.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.89 | $12.09 |
| 52-week low | $3.16 | $2.52 |
| Distance from 52-week high | -58.96% | -79.07% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +334.43% | +571.94% |
| Average volume | 139.16K | 195.17K |
| Shares outstanding | 14.54M | 28.81M |
| Employees | 14 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CING has outperformed NTHI by 95.0 percentage points over the past year.
About Cingulate
CING stock →Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults.
Healthcare · Biotechnology · 14 employees
About NeOnc Technologies
NTHI stock →NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers.
Healthcare · Biotechnology · 5 employees
CING vs NTHI FAQ
Which is bigger, Cingulate or NeOnc Technologies?
NeOnc Technologies (NTHI) is larger, with a market capitalization of $72.88M compared with $70.96M for Cingulate (CING).
Which stock has performed better over the past year, CING or NTHI?
CING returned +15.91% over the past 12 months, compared with -79.07% for NTHI (price return, excluding dividends). Past performance does not predict future results.
Are Cingulate and NeOnc Technologies in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.